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Summary A rare case of peritonitis due to beta-lactamase-negative, ampicillin-resistant
Haemophilus influenzae is described in an 18-year-old male undergoing automated peritoneal
dialysis. The infection was probably of respiratory origin. Two strains of H. influenzae cultured
from peritoneal fluid and a nasal swab were indistinguishable by molecular methods. The patient
was successfully treated with oral ciprofloxacin. The authors suggest that this species should be
taken into account as the etiologic agent of peritoneal dialysis-associated peritonitis. Targeted
antimicrobial therapy should be based on local antibiotic resistance patterns.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Bacterial peritonitis is a disease frequently occurring in
patients with continuous ambulatory peritoneal dialysis
(CAPD) and automated peritoneal dialysis (APD), mainly in
a first year of treatment.1 The most common bacterial
species causing this complication are the coagulase-negative
staphylococci, Staphylococcus aureus, and streptococci.2* Corresponding author. Tel.: +48 22 851 46 70;
fax: +48 22 841 29 49.
E-mail address: kadlubek@cls.edu.pl (M. Kadłubowski).
1201-9712/$36.00 # 2009 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2009.01.001Haemophilus influenzae, although frequently isolated from
respiratory tract infections, is rarely associated with perito-
nitis, and there are only few reports of such cases in the
literature.3—6 Here we report the first case of APD-associated
peritonitis caused by non-typeable H. influenzae showing the
beta-lactamase-negative, ampicillin-resistant (BLNAR) phe-
notype.
Case report
The patient was an 18-year-old male with end-stage renal
disease (ESRD) due to systemic lupus erythematosus (SLE),Published by Elsevier Ltd. All rights reserved.
APD-associated peritonitis due to H. influenzae e471treated with APD since February 2007. At the end of January
2008 he was admitted to hospital with a diagnosis of APD-
associated peritonitis. The patient was in no distress, was
afebrile, and was complaining of abdominal pain and vomit-
ing. Samples of dialysis fluid, blood, and a nasal swab were
obtained and sent to a local laboratory for diagnostic pro-
cedures. Intraperitoneal antimicrobial therapy with vanco-
mycin and ceftazidime was initiated.
Laboratory tests demonstrated a white blood cell (WBC)
count of 8.6  109/l with 84% neutrophils and 9% lympho-
cytes, hemoglobin of 100 g/l, and a platelet count of
317  109/l.
Dialysis fluid obtained from the patient on the day of
admission was turbid and showed a pleocytosis: 435  106
WBC/l, with 45% neutrophils and 49% lymphocytes.
A pure culture of Gram-negative coccobacillus was iso-
lated from the dialysis fluid at a local laboratory. Using
standard methods the isolate was identified as a non-type
b and beta-lactamase-negative, ampicillin-resistant (BLNAR)
H. influenzae. It was sent to the National Reference Centre
for Bacterial Meningitis (NRCBM) in Warsaw for confirmation
of the resistance mechanism and further analysis. Addition-
ally, the same bacterial species was isolated from a nasal
swab taken from the patient. This isolate was also included in
the analysis. Blood cultures taken from the patient were
negative.
After the identification of the agent of infection and
evaluation of its susceptibility, vancomycin with ceftazidime
was discontinued and the patient was treated with oral
ciprofloxacin. The treatment was successful and symptoms
rapidly subsided. Control diagnostic tests, performed after
two days of therapy, showed a rapid decrease in peritoneal
cytosis to the value of 15  106 WBC/l. Control cultures of
dialysis fluid and blood were negative. After two weeks of
treatment the patient was discharged from the hospital in a
good condition.
At the NRCBM both isolates were confirmed by the com-
mercial test Api NH (bioMe´rieux, Marcy l’Etoille, France) as
H. influenzae, biotype II. A PCR method7 classified isolates as
non-typeable (NTHi). Their genetic relatedness was checked
by AP-PCR (arbitrarily-primed PCR)8 and pulsed-field gel
electrophoresis. The isolates studied were indistinguishable
by all the methods applied, which indicates the respiratory
origin of the peritoneal infection as the most probable.
Multilocus sequence typing (MLST) analysis of the isolates
was performed and identified them as ST-367 sequence type.
Antimicrobial susceptibility of isolates to ampicillin,
amoxicillin—clavulanic acid, cefotaxime, meropenem, chlor-
amphenicol, ciprofloxacin, and rifampin was determined at
the NRCBM by the commercial E-test method (AB Biodisk,
Solna, Sweden) following the manufacturer’s recommenda-
tions and interpreted according to the Clinical and Labora-
tory Standards Institute (CLSI) guidelines.9 Beta-lactamase
production was evaluated by the test using a nitrocefin disk.
Both isolates studied were beta-lactamase negative and in
vitro intermediately resistant to ampicillin (minimum inhi-
bitory concentration (MIC) = 1.5 g/l), resistant to amoxicil-
lin—clavulanic acid (MIC = 4.0 g/l), and susceptible to the
rest of antimicrobials tested.
The molecular mechanism underlying the BLNAR pheno-
type in the isolates was confirmed by the PCR-based
method.10,11 To identify exact amino acid substitutions inpenicillin-binding protein PBP3, resulting in decreased affi-
nity to beta-lactams, the sequence analysis of the 1 kb
transpeptidase domain-coding fragment of the ftsI gene was
performed, as described by Kubota et al.12 Analysis of the
obtained sequence (EMBL nucleotide accession number
FM204880) revealed the following substitutions in the
PBP3 fragment, specific for BLNAR strains: Asp350 was
replaced with Asn, Met377 was changed into Ile, Ala502
and Asn526 were replaced by Val and Lys, respectively. These
changes classified this strain in BLNAR group IIb, according to
the classification proposed by Dabernat et al.13
Discussion
Haemophilus influenzae is a bacterium frequently colonizing
the nasopharynx of healthy individuals, and the carriage
state usually does not cause any signs of infection. In some
cases the bacteria can disseminate and proliferate in differ-
ent body compartments (sinuses, middle ear, blood, cere-
brospinal fluid, etc.), causing a variety of symptoms, from
localized respiratory tract infections to a life-threatening
septicemia. There are few reports describing this species as
the etiologic agent of peritonitis. As Musher et al. suggested,
there is a possibility that bacteria can be transferred from the
respiratory tract to the peritoneal fluid via the bloodstream.6
According to the literature, in such cases the state of bac-
teremia is temporary, and blood cultures are often negative.
Beta-lactams are the major group of chemotherapeutics
used to treat H. influenzae infections. Beta-lactamase pro-
duction is the most frequent resistance mechanism in this
species.14 Other mechanisms have been reported, such as
alterations in penicillin-binding proteins, resulting in their
decreased affinity to beta-lactams and underlying the BLNAR
phenotype. Although BLNAR strains are still rarely isolated in
the USA,9,10 in some countries, such as Japan, their preva-
lence among clinical isolates ofH. influenzae is very high.15 In
others, such as Spain or Poland, the frequency of isolation of
BLNAR strains is increasing.11,16
This and previously described cases show that H. influen-
zae should be taken into account as a possible etiologic agent
of CAPD- and APD-associated peritonitis. The fact that this
species is relatively rarely identified as a cause of this con-
dition can result from its high nutrition requirements, which
make it impossible to grow on standard microbiological
media. A clinical decision concerning targeted antimicrobial
therapy should always be based on local antibiotic resistance
patterns. In countries where the BLNAR phenotype is fre-
quently identified in H. influenzae strains, identification of
this species as a cause of any invasive infection requires
screening for a possible BLNAR phenotype.
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